FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285623> ?p ?o ?g. }

• W4379285623 endingPage "549" @default.
• W4379285623 startingPage "549" @default.
• W4379285623 abstract "549 Background: Patients with early-stage hormone receptor-positive (HR+) breast cancer have a good prognosis. Prior studies have shown that extending endocrine therapy beyond the first 5 years reduces the risk of late distant recurrence. The Breast Cancer Index (BCI) is a gene expression assay that provides both a prognostic risk of late distant recurrence in addition to a yes/no prediction of benefit from receiving extended endocrine therapy. To date, no studies have examined the relationship between race and BCI score. This study aims to investigate the interaction between race and BCI scores in women with early-stage HR+ breast cancer. Methods: We analyzed BCI scores, demographics, and tumor characteristics from 89 women diagnosed with early-stage HR+ breast cancer. Univariate logistic regression analysis was run using race, BCI recurrence risk, hormone status, tumor size, or tumor grade as predictor variables. BCI prediction of benefit was used as the outcome variable. Results: Compared to Caucasians, Native Hawaiians had significantly greater odds of having a BCI score predicting benefit from receiving extended endocrine therapy (OR = 7.00, p = 0.04). Additionally, there were significantly greater odds of having a score predicting benefit among those who had a recurrence risk of 5-10% (OR = 3.84, p = 0.04), or ≥10% (OR = 9.16, p < 0.001) compared to a recurrence risk < 5%. Conclusions: Our findings highlight the utility of characterizing differences in BCI predictive and prognostic scores by race among breast cancer patients with early-stage HR+ tumors. Notably, Native Hawaiian women had 7.0 times increased odds of having a score predicting benefit of extended endocrine therapy compared to Caucasians. This result is salient given the high incidence of breast cancer among Native Hawaiians. Though not statistically significant, our data also demonstrated Filipinos had increased odds of a score predicting benefit as well. Furthermore, our findings show a direct correlation between prognostic risk of late distant recurrence and predictive benefit of extended endocrine therapy with a higher odds ratio associated with higher recurrence risk. Our study shows notable differences in BCI findings when stratifying patients by race. However, our sample size is relatively small, and we lack sufficient data from patients representing other races such as Hispanic and Black. Future studies may expand the sample size and adjust for known breast cancer risk factors. The goal is to identify trends that may improve our usage of the BCI as a tool to effectively guide hormone therapy recommendations in patients with early-stage HR+ breast cancer. [Table: see text]" @default.
• W4379285623 created "2023-06-05" @default.
• W4379285623 creator A5031330914 @default.
• W4379285623 creator A5065436480 @default.
• W4379285623 creator A5092084590 @default.
• W4379285623 date "2023-06-01" @default.
• W4379285623 modified "2023-09-30" @default.
• W4379285623 title "An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race." @default.
• W4379285623 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.549" @default.
• W4379285623 hasPublicationYear "2023" @default.
• W4379285623 type Work @default.
• W4379285623 citedByCount "0" @default.
• W4379285623 crossrefType "journal-article" @default.
• W4379285623 hasAuthorship W4379285623A5031330914 @default.
• W4379285623 hasAuthorship W4379285623A5065436480 @default.
• W4379285623 hasAuthorship W4379285623A5092084590 @default.
• W4379285623 hasConcept C121608353 @default.
• W4379285623 hasConcept C126322002 @default.
• W4379285623 hasConcept C143998085 @default.
• W4379285623 hasConcept C144301174 @default.
• W4379285623 hasConcept C146357865 @default.
• W4379285623 hasConcept C151730666 @default.
• W4379285623 hasConcept C151956035 @default.
• W4379285623 hasConcept C156957248 @default.
• W4379285623 hasConcept C38180746 @default.
• W4379285623 hasConcept C530470458 @default.
• W4379285623 hasConcept C71924100 @default.
• W4379285623 hasConcept C86803240 @default.
• W4379285623 hasConceptScore W4379285623C121608353 @default.
• W4379285623 hasConceptScore W4379285623C126322002 @default.
• W4379285623 hasConceptScore W4379285623C143998085 @default.
• W4379285623 hasConceptScore W4379285623C144301174 @default.
• W4379285623 hasConceptScore W4379285623C146357865 @default.
• W4379285623 hasConceptScore W4379285623C151730666 @default.
• W4379285623 hasConceptScore W4379285623C151956035 @default.
• W4379285623 hasConceptScore W4379285623C156957248 @default.
• W4379285623 hasConceptScore W4379285623C38180746 @default.
• W4379285623 hasConceptScore W4379285623C530470458 @default.
• W4379285623 hasConceptScore W4379285623C71924100 @default.
• W4379285623 hasConceptScore W4379285623C86803240 @default.
• W4379285623 hasFunder F4320332161 @default.
• W4379285623 hasIssue "16_suppl" @default.
• W4379285623 hasLocation W43792856231 @default.
• W4379285623 hasOpenAccess W4379285623 @default.
• W4379285623 hasPrimaryLocation W43792856231 @default.
• W4379285623 hasRelatedWork W1999960801 @default.
• W4379285623 hasRelatedWork W2031298774 @default.
• W4379285623 hasRelatedWork W2032808049 @default.
• W4379285623 hasRelatedWork W2082392604 @default.
• W4379285623 hasRelatedWork W2224319365 @default.
• W4379285623 hasRelatedWork W2245189862 @default.
• W4379285623 hasRelatedWork W2554003122 @default.
• W4379285623 hasRelatedWork W3160736738 @default.
• W4379285623 hasRelatedWork W377899687 @default.
• W4379285623 hasRelatedWork W4312362032 @default.
• W4379285623 hasVolume "41" @default.
• W4379285623 isParatext "false" @default.
• W4379285623 isRetracted "false" @default.
• W4379285623 workType "article" @default.